Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine vs Endocrine Therapy as Maintenance in HR+/HER2- Metastatic Breast Cancer
NCT03204734Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine in breast cancer (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03204734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204734.